The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs
Abstract
Cutaneous sarcoidosis is a granulomatous skin disease associated with significant quality-of-life impairment. Evidence from randomized controlled trials (RCTs) guiding systemic or targeted therapy remains limited. To assess the efficacy and safety of pharmacological therapies for cutaneous sarcoidosis in randomized placebo-controlled trials PubMed, the Cochrane Library, and ClinicalTrials.gov were searched through January 2025. Eligible studies were RCTs including adults with cutaneous sarcoidosis randomized to pharmacological therapy versus placebo. Outcomes were clinical response, quality of life, and serious adverse events (SAEs). Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random-effects models. Six RCTs including 156 participants were analyzedanalysed. Pharmacological therapies did not significantly improve clinical response compared with placebo (OR 2.24; 95% CI, 0.73-6.90; p=0.16). A non-significant trend toward improved quality of life was observed (OR 2.23; 95% CI, 0.87-5.73; p=0.09). No significant difference in SAEsserious adverse events was found between groups (OR 0.97; 95% CI, 0.48-1.96; p=0.93). Risk of bias ranged from moderate to high, with low statistical heterogeneity. Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life. Larger, well-designed RCTs are needed.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 156 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.